Eliminating innovation: how price controls limit access.
作者信息
Ingram Jonathan
机构信息
Southern Illinois University, USA.
出版信息
J Leg Med. 2011 Jan;32(1):115-28. doi: 10.1080/01947648.2011.550833.
PMID:21391059
Abstract
摘要
相似文献
1
Eliminating innovation: how price controls limit access.消除创新：价格管制如何限制可及性。
J Leg Med. 2011 Jan;32(1):115-28. doi: 10.1080/01947648.2011.550833.
2
The need for health care reform.医疗保健改革的必要性。
Health Syst Rev. 1994 May-Jun;27(3):5-6.
3
Can price and regulatory controls replace free market competition in the drug industry?价格和监管控制能否取代制药行业的自由市场竞争？
Healthspan. 1993 Nov;10(10):30-2.
4
Price controls for drugs.药品价格管制
J Med Assoc Ga. 1995 Mar;84(3):135-6.
5
The Clinton proposal and old-age-based rationing: a plea for informed public debate.克林顿的提议与基于年龄的医疗资源分配：呼吁开展有见地的公众辩论。
J Aging Soc Policy. 1994;6(1-2):167-77. doi: 10.1300/J031v06n01_10.
6
An Rx for reform: a Medicare prescription drug benefit.改革良方：医疗保险处方药福利
Health Matrix Clevel. 2002 Summer;12(2):449-505.
7
Do we have to sacrifice access and quality to cut costs?我们必须以牺牲医疗可及性和质量为代价来削减成本吗？
Minn Med. 2004 Oct;87(10):35, 52.
8
Drug card setback highlights need for cost relief.药品卡受挫凸显了降低成本的必要性。
Healthc Financ Manage. 2003 Apr;57(4):50-4.
9
Health care reform and the pharmaceutical industry.医疗保健改革与制药行业。
Health Care Manag. 1994 Aug;1(1):187-96.
10
Dueling spending projections. OMB pins $534 billion price tag on Rx benefit.两种不同的支出预测。美国行政管理和预算局预计处方药福利的成本为5340亿美元。
Mod Healthc. 2004 Feb 2;34(5):10-1.
Zotero 插件